In such environment, inhibition of BRD4 has greater consequences that on regular ENHs conferring to SE-associated genes a higher magnitude of susceptibility to BETi and explaining at least in part the cancer selective activity of these drugs (Fig. 1b). The gene discussed is BRD4; the disease is cancer.